TP53 and breast carcinoma: In another study from India consisting of 40 patients with early-stage HR+ breast cancer, the most common mutations were PIK3CA (38%), ESR1 (34.5%), TP53 (28.1%), BRCA1 (21.8%), and BRCA2 (25%).